Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer

BACKGROUND:  Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers with an estimated prevalence of less than 1% across all solid tumors. Tropomyosin receptor kinase inhibitors (TRKis) block the constitutively activated tyrosine receptor kinase (TRK) fusion protein produced...

Descripción completa

Detalles Bibliográficos
Autores principales: Klink, Andrew J., Kavati, Abhishek, Gassama, Awa T., Kozlek, Tom, Gajra, Ajeet, Antoine, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217884/
https://www.ncbi.nlm.nih.gov/pubmed/35716252
http://dx.doi.org/10.1007/s11523-022-00887-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217884/
https://www.ncbi.nlm.nih.gov/pubmed/35716252
http://dx.doi.org/10.1007/s11523-022-00887-w

Ejemplares similares